Potential enhancements to improve CAR‐T cell efficacy for solid tumours include incorporating cytokine support (e.g., IL‐15 or IL‐12) to enhance survival, developing dual or multi‐antigen targeting to prevent tumour escape, and using CRISPR/Cas9 technology to knock out inhibitory receptors. Here, IL15 is linked to neoplasm.